Deferiprone-d₃

Deferiprone-d₃ is intended for use as an internal standard for the quantification of deferiprone (Item No. 20387) by GC- or LC-MS. Deferiprone is an iron chelator that binds to iron in a 3:1 (ligand:iron) ratio and has antioxidant and neuroprotective activities.¹ It reverses ferroptosis induced by erastin (Item No. 17754) in HT-1080 fibrosarcoma cells when used at a concentration of 100 µM as well as reduces levels of intracellular iron and inhibits lipid peroxidation in primary rat hepatocytes at 200 and 50 µM, respectively.^2,3 Deferiprone reduces cholesterol diet-induced increases in the levels of amyloid-β (1-42) (Aβ42), Aβ40, and the phosphorylation of tau and glycogen synthase kinase-3β (GSK-3β) in the rabbit hippocampus when administered at a dose of 50 mg/kg.⁴ Formulations containing deferiprone have been used in the treatment of thalassemia.

WARNING This product is not for human or veterinary use.

1. Barnabé, N., Zastre, J.A., Venkataram, S., et al. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic. Biol. Med. 33(2), 266-275 (2002).

2. Zheng, J., Sato, M., Mishima, E., et al. Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines. Cell Death Dis. 12(7), 698 (2021).

3. Morel, I., Cillard, J., Lescoat, G., et al. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: Comparison of their mechanism of protection with that of desferrioxamine. Free Radic. Biol. Med. 13(5), 499-508 (1992).

4. Prasanthi, J.R., Schrag, M., Dasari, B., et al. Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet. J. Alzheimers Dis. 30(1), 167-182 (2012).